Journal article
A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis
Abstract
We report a case of dermatomyositis in a 59-year old female with advanced non-small-cell lung cancer post one cycle of first-line pembrolizumab monotherapy. Her symptoms resolved with high-dose methyl-prednisolone and subsequent prolonged oral prednisone taper over 11 weeks. She achieved durable response over 6 months without further pembrolizumab and was successfully rechallenged without recurrent high-grade immunotoxicity. To our knowledge, …
Authors
Kartolo A; Towheed T; Mates M
Journal
Immunotherapy, Vol. 13, No. 6, pp. 477–481
Publisher
Taylor & Francis
Publication Date
April 2021
DOI
10.2217/imt-2020-0309
ISSN
1750-743X